EU Indication Extensions On Cards For Taltz, Truvada and Yervoy

Eli Lilly, Gilead and Bristol-Myers Squibb can look forward to product indication extensions after getting the OK from the European Medicines Agency’s CHMP. Other companies seeking extensions will be asked for more information.

Circles
Product indications are often expanded after the initial approval • Source: Shutterstock

Just three out of the 15 requests for extensions of therapeutic indications that the European Medicines Agency’s Committee for Medicinal Products for Human Use considered for adoption at its latest meeting got the okay. No opinions were given on the remaining 12, meaning the CHMP will request supplementary information from the applicants in question.

The three successful applicants were Eli Lilly, Gilead Sciences, and Bristol-Myers Squibb. The products were, respectively, Taltz (ixekizumab), Truvada (emtricitabine/tenofovir...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Europe

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

  • EU Pharma Reform: What You Need to Know Now

     

    As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

  • New EU Approvals

    <p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Geography